ABCELLERA BIOLOGICS INC (ABCL) Stock Price, Quote, News and Overview
NASDAQ:ABCL - Nasdaq - CA00288U1066 - Common Stock - Currency: USD
ABCL Quote, Performance and Key Statistics
3.49
+0.06 (+1.75%)
The current stock price of ABCL is 3.49 USD. In the past month the price increased by 63.08%. In the past year, price increased by 29.74%.
ABCL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 19.25 | 159.10B | ||
| DHR | DANAHER CORP | 26.99 | 143.92B | ||
| A | AGILENT TECHNOLOGIES INC | 22.31 | 34.34B | ||
| IQV | IQVIA HOLDINGS INC | 14.39 | 28.13B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 29.79 | 25.05B | ||
| WAT | WATERS CORP | 29.98 | 21.25B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 33.5 | 15.98B | ||
| ILMN | ILLUMINA INC | 29.47 | 15.54B | ||
| ICLR | ICON PLC | 10.85 | 11.83B | ||
| RVTY | REVVITY INC | 20.09 | 11.67B | ||
| QGEN | QIAGEN N.V. | 20.96 | 10.44B | ||
| TEM | TEMPUS AI INC | N/A | 10.29B |
Related stock screener links
About ABCL
Company Profile
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 596 full-time employees. The company went IPO on 2020-12-11. The Company’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the antibody discovery problems. The firm has developed technology platforms to unlock drug classes, targets, and modalities, including transmembrane proteins, T-cell engagers, and peptide-MHCs. The firm is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two preclinical programs in its internal pipeline are ABCL575 and ABCL635. ABCL635 is an antibody-drug candidate against an undisclosed target with an indication in metabolic and endocrine conditions. ABCL575 targets OX40 ligand and is being developed as a therapy for the treatment of atopic dermatitis and other indications of autoimmunity and inflammation.
Company Info
ABCELLERA BIOLOGICS INC
150 W 4Th Avenue
Vancouver BRITISH COLUMBIA CA
Employees: 586
Phone: 16045599005
ABCELLERA BIOLOGICS INC / ABCL FAQ
What is the stock price of ABCELLERA BIOLOGICS INC today?
The current stock price of ABCL is 3.49 USD. The price increased by 1.75% in the last trading session.
What is the ticker symbol for ABCELLERA BIOLOGICS INC stock?
The exchange symbol of ABCELLERA BIOLOGICS INC is ABCL and it is listed on the Nasdaq exchange.
On which exchange is ABCL stock listed?
ABCL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ABCELLERA BIOLOGICS INC stock?
15 analysts have analysed ABCL and the average price target is 8.6 USD. This implies a price increase of 146.34% is expected in the next year compared to the current price of 3.49. Check the ABCELLERA BIOLOGICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ABCELLERA BIOLOGICS INC worth?
ABCELLERA BIOLOGICS INC (ABCL) has a market capitalization of 1.04B USD. This makes ABCL a Small Cap stock.
How many employees does ABCELLERA BIOLOGICS INC have?
ABCELLERA BIOLOGICS INC (ABCL) currently has 586 employees.
What are the support and resistance levels for ABCELLERA BIOLOGICS INC (ABCL) stock?
ABCELLERA BIOLOGICS INC (ABCL) has a support level at 3.11. Check the full technical report for a detailed analysis of ABCL support and resistance levels.
Is ABCELLERA BIOLOGICS INC (ABCL) expected to grow?
The Revenue of ABCELLERA BIOLOGICS INC (ABCL) is expected to decline by -35.96% in the next year. Check the estimates tab for more information on the ABCL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ABCELLERA BIOLOGICS INC (ABCL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ABCL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ABCL, evaluating the profitability, health, valuation and growth aspects
- ABCELLERA BIOLOGICS INC (ABCL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ABCELLERA BIOLOGICS INC (ABCL) Sales and EPS estimates to see what analysts future expectations are.
- ABCELLERA BIOLOGICS INC (ABCL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ABCELLERA BIOLOGICS INC (ABCL) Insider and Institutional Ownership to learn about the owners and their transactions.
- ABCELLERA BIOLOGICS INC (ABCL) Stock Chart to make your own analysis
- ABCELLERA BIOLOGICS INC (ABCL) Latest news and press-releases to stay up to date.
Does ABCELLERA BIOLOGICS INC (ABCL) stock pay dividends?
ABCL does not pay a dividend.
When does ABCELLERA BIOLOGICS INC (ABCL) report earnings?
ABCELLERA BIOLOGICS INC (ABCL) will report earnings on 2025-08-04, after the market close.
What is the Price/Earnings (PE) ratio of ABCELLERA BIOLOGICS INC (ABCL)?
ABCELLERA BIOLOGICS INC (ABCL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).
What is the Short Interest ratio of ABCELLERA BIOLOGICS INC (ABCL) stock?
The outstanding short interest for ABCELLERA BIOLOGICS INC (ABCL) is 11.75% of its float. Check the ownership tab for more information on the ABCL short interest.
ABCL Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ABCL. When comparing the yearly performance of all stocks, ABCL is one of the better performing stocks in the market, outperforming 91.6% of all stocks.
ABCL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ABCL. No worries on liquidiy or solvency for ABCL as it has an excellent financial health rating, but there are worries on the profitability.
ABCL Financial Highlights
Over the last trailing twelve months ABCL reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS decreased by -7.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.49% | ||
| ROE | -16.41% | ||
| Debt/Equity | 0 |
ABCL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ABCL. The Buy consensus is the average rating of analysts ratings from 15 analysts.
For the next year, analysts expect an EPS growth of -23.72% and a revenue growth -35.96% for ABCL